Abstract
Dithiocarbamates and their complexes with transition metals have been used as common pesticides, vulcanizing or analytical agents for decades. These compounds are one of the most reported inhibitors of nuclear factor-κB (NF-κB) signaling cascade. Recently, it has been found that dithiocarbamates are very potent inhibitors of proteasome. NF-κB plays a central role in the immune system and is described as a major actor in many of human cancers mainly because of its protective effects against apoptosis. Molecular mechanisms involved in regulation and function of NF-κB pathway have been elucidated recently. In particular, pivotal zinc containing proteins that alter NF-κB signal transduction were recognized. Additionally, proteasome system was found to be a key player in NF-κB pathway and is an attractive target for anticancer drug development. Collectively, the capability of dithiocarbamates to inhibit NF-κB and proteasome makes these compounds promising anticancer agents. This review focuses on the biological activity of dithiocarbamate coordination compounds with regard to their possible molecular targets in NF-κB signaling and proteasome (JAMM domain proteins). Future research should aim to find the most suitable dithiocarbamate coordination compounds for treatment of cancer and other diseases.
Keywords: Disulfiram, Diethyldithiocarbamate (DDTC), Pyrrolidinedithiocarbamate (PDTC), Metal dithiocarbamates, NF-κB, Proteasome, JAMM
Current Pharmaceutical Design
Title: Targeting of Nuclear Factor-κB and Proteasome by Dithiocarbamate Complexes with Metals
Volume: 13 Issue: 30
Author(s): B. Cvek and Z. Dvorak
Affiliation:
Keywords: Disulfiram, Diethyldithiocarbamate (DDTC), Pyrrolidinedithiocarbamate (PDTC), Metal dithiocarbamates, NF-κB, Proteasome, JAMM
Abstract: Dithiocarbamates and their complexes with transition metals have been used as common pesticides, vulcanizing or analytical agents for decades. These compounds are one of the most reported inhibitors of nuclear factor-κB (NF-κB) signaling cascade. Recently, it has been found that dithiocarbamates are very potent inhibitors of proteasome. NF-κB plays a central role in the immune system and is described as a major actor in many of human cancers mainly because of its protective effects against apoptosis. Molecular mechanisms involved in regulation and function of NF-κB pathway have been elucidated recently. In particular, pivotal zinc containing proteins that alter NF-κB signal transduction were recognized. Additionally, proteasome system was found to be a key player in NF-κB pathway and is an attractive target for anticancer drug development. Collectively, the capability of dithiocarbamates to inhibit NF-κB and proteasome makes these compounds promising anticancer agents. This review focuses on the biological activity of dithiocarbamate coordination compounds with regard to their possible molecular targets in NF-κB signaling and proteasome (JAMM domain proteins). Future research should aim to find the most suitable dithiocarbamate coordination compounds for treatment of cancer and other diseases.
Export Options
About this article
Cite this article as:
Cvek B. and Dvorak Z., Targeting of Nuclear Factor-κB and Proteasome by Dithiocarbamate Complexes with Metals, Current Pharmaceutical Design 2007; 13 (30) . https://dx.doi.org/10.2174/138161207782110390
DOI https://dx.doi.org/10.2174/138161207782110390 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Novel Etomidate Derivatives
Current Pharmaceutical Design Monoclonal Antibodies in Clinical Oncology
Anti-Cancer Agents in Medicinal Chemistry Intravitreal Anti-VEGF Drugs as Adjuvant Therapy in Diabetic Retinopathy Surgery
Current Diabetes Reviews Industrial Chemicals and Acute Lung injury with a Focus on Exposure Scenarios
Current Respiratory Medicine Reviews An Overview of Olive Oil Biomolecules
Current Biotechnology Isoniazid: Metabolic Aspects and Toxicological Correlates
Current Drug Metabolism Effects of Kallistatin on Oxidative Stress and Inflammation on Renal Ischemia-Reperfusion Injury in Mice
Current Vascular Pharmacology Solubility Enhancement and Delivery Systems of Curcumin a Herbal Medicine: A Review
Current Drug Delivery Biologics and the Cardiovascular System: A Double-Edged Sword
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Alogliptin; A Review of a New Dipeptidyl Peptidase-4 (DPP-4) Inhibitor for the Treatment of Type 2 Diabetes Mellitus
Cardiovascular & Hematological Disorders-Drug Targets Protein-Energy Malnutrition Alters Thermoregulatory Homeostasis and the Response to Brain Ischemia
Current Neurovascular Research Hemodynamic Monitoring in the Acute Management of Pediatric Heart Failure
Current Cardiology Reviews Adenosine A<sub>3</sub> Receptor: A promising therapeutic target in cardiovascular disease
Current Cardiology Reviews Pharmacological Targets for the Inhibition of Neurogenic Inflammation
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Bortezomib – First Therapeutic Proteasome Inhibitor for Cancer Therapy: A Review of Patent Literature
Recent Patents on Anti-Cancer Drug Discovery Single-dose Pharmacokinetics and Tolerability of Oral Delta-9- Tetrahydrocannabinol in Patients with Amyotrophic Lateral Sclerosis
Drug Metabolism Letters Fused 1,4-Dihydropyridines as Potential Calcium Modulatory Compounds
Mini-Reviews in Medicinal Chemistry Atypical Manifestations of Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Children: A Systematic Review
Current Pediatric Reviews Effects of Estrogen in Gender-dependent Fetal Programming of Adult Cardiovascular Dysfunction
Current Vascular Pharmacology Imidazole: An Essential Edifice for the Identification of New Lead Compounds and Drug Development
Mini-Reviews in Medicinal Chemistry